Gan and Terri Lucas for coordinating our animal facility use. We thank Julie Fuller for tissue processing. We’re grateful to Tam How, Catherine Gatza, Alison Meyer, Alisha Holtzhausen, Catherine Lavau, Rebekah Moehring, Jennifer Elderbroom, Rachel Hesler, and Jasmine Nee for technical assistance and Cheryl Alles for superior clerical assistance. We’re grateful to Daniel Wechsler, Dona Chikaraishi, Christopher Kontos, and Julio Ramirez for invaluable mentoring all through this project. This operate was supported in aspect by NIH grants F30 CA168043-01 (to E.H. Knelson), R01-CA136786 (to G.C. Blobe), and R01-CA135006 (to G.C. Blobe). Received for publication March 1, 2013, and accepted in revised type August 8, 2013. Address correspondence to: Gerard C. Blobe, Duke University Health-related Center, Box 91004, Durham, North Carolina 27708, USA.Price of 6-Chloro-5-methylpyridazin-3(2H)-one Telephone: 919.668.1359; Fax: 919.681.6906; E-mail: [email protected] 123 Quantity 11 Novemberhttp://jci.orgresearch article1. National Cancer Institute. Surveillance, Epidemiology and End Outcomes (SEER) Database. NIH Net web site. http://seer.cancer.gov/. Accessed August 30, 2013. 2. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD. Neuroblastoma: contemporary management. Arch Dis Child Educ Pract Ed. 2009;94(6):177?85.Boc-Ser-OtBu web three.PMID:35227773 Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106?120. 4. De Bernardi B, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008; 26(ten):1710?716. five. Retrosi G, et al. Morbidity right after ganglioneuroma excision: is surgery needed? Eur J Pediatr Surg. 2011;21(1):33?7. 6. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566?579. 7. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202?211. 8. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; three(3):203?16. 9. Seeger RC, et al. Association of various copies in the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111?116. 10. Schwab M, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines as well as a neuroblastoma tumour. Nature. 1983;305(5931):245?48. 11. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21(4):256?66. 12. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144?57. 13. Matthay KK, et al. Long-term final results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27(7):1007?013. 14. Edsjo A, Holmquist L, Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol. 2007;17(three):248?56. 15. Gilbert SF. The neural crest. In: Developmental Biology. Sunderland, Massachusetts, USA: Sinauer Associates; 2000. 16. Iolascon A, et al. Lowered expression of transforming development factor-beta receptor sort III in high stage neuroblastomas. Br J Cancer. 2000; 82(six):1171?176. 17. McCune BK, Patterson K, Chandra RS, Kapur S, Sporn MB, Tsokos M. Expression of transforming growth factor-beta isoforms in tiny round cell tumors of childhood. An immunohistochemical study. Am J P.
